Who are Eylea HD (aflibercept HD)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ziv aflibercept, Eylea® Solution for intravitreal injection, Deferred aflibercept, Prompt aflibercept.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eylea-hd-aflibercept-hd.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Eylea HD (aflibercept HD) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eylea HD (aflibercept HD) (Eylea HD (aflibercept HD)) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor / Antiangiogenic agent. Area: Ophthalmology.

phase 3 VEGF inhibitor / Antiangiogenic agent VEGF-A, PlGF (Placental Growth Factor) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Eylea HD (aflibercept HD) (Eylea HD (aflibercept HD)) — Alvotech Swiss AG. Eylea HD is a high-dose formulation of aflibercept, a VEGF trap that binds and inhibits vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Eylea HD (aflibercept HD) TARGET	Eylea HD (aflibercept HD)	Alvotech Swiss AG	phase 3	VEGF inhibitor / Antiangiogenic agent	VEGF-A, PlGF (Placental Growth Factor)
Ziv aflibercept	Ziv aflibercept	Marashi Eye Clinic	marketed	VEGF inhibitor / Antiangiogenic agent	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Eylea® Solution for intravitreal injection	Eylea® Solution for intravitreal injection	Rophibio, Inc.	phase 3	VEGF inhibitor / Antiangiogenic agent	VEGF-A, VEGF-B, PlGF (placental growth factor)
Deferred aflibercept	Deferred aflibercept	Jaeb Center for Health Research	phase 3	VEGF inhibitor / Antiangiogenic agent	VEGF (vascular endothelial growth factor), PlGF (placental growth factor)
Prompt aflibercept	Prompt aflibercept	Jaeb Center for Health Research	phase 3	VEGF inhibitor / Antiangiogenic agent	VEGF (vascular endothelial growth factor), PlGF (placental growth factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor / Antiangiogenic agent class)

Jaeb Center for Health Research · 2 drugs in this class
Alvotech Swiss AG · 1 drug in this class
Marashi Eye Clinic · 1 drug in this class
Rophibio, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eylea HD (aflibercept HD) — Competitive Intelligence Brief. https://druglandscape.com/ci/eylea-hd-aflibercept-hd. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing